SNDL INC (SNDL) Stock Fundamental Analysis

NASDAQ:SNDL • CA83307B1013

1.58 USD
+0.04 (+2.6%)
At close: Feb 20, 2026
1.572 USD
-0.01 (-0.51%)
After Hours: 2/20/2026, 8:05:30 PM
Fundamental Rating

4

Overall SNDL gets a fundamental rating of 4 out of 10. We evaluated SNDL against 192 industry peers in the Pharmaceuticals industry. The financial health of SNDL is average, but there are quite some concerns on its profitability. SNDL has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year SNDL has reported negative net income.
  • SNDL had a positive operating cash flow in the past year.
  • SNDL had negative earnings in each of the past 5 years.
  • SNDL had negative operating cash flow in 4 of the past 5 years.
SNDL Yearly Net Income VS EBIT VS OCF VS FCFSNDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -7.00%, SNDL is in the better half of the industry, outperforming 71.35% of the companies in the same industry.
  • With a decent Return On Equity value of -8.39%, SNDL is doing good in the industry, outperforming 76.56% of the companies in the same industry.
Industry RankSector Rank
ROA -7%
ROE -8.39%
ROIC N/A
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
SNDL Yearly ROA, ROE, ROICSNDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • SNDL has a Gross Margin (27.03%) which is in line with its industry peers.
  • SNDL's Gross Margin has been stable in the last couple of years.
  • SNDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
SNDL Yearly Profit, Operating, Gross MarginsSNDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

6

2. Health

2.1 Basic Checks

  • SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SNDL remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, SNDL has more shares outstanding
  • The debt/assets ratio for SNDL has been reduced compared to a year ago.
SNDL Yearly Shares OutstandingSNDL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
SNDL Yearly Total Debt VS Total AssetsSNDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • SNDL has an Altman-Z score of 1.14. This is a bad value and indicates that SNDL is not financially healthy and even has some risk of bankruptcy.
  • SNDL has a Altman-Z score of 1.14. This is comparable to the rest of the industry: SNDL outperforms 55.73% of its industry peers.
  • SNDL has a debt to FCF ratio of 2.69. This is a good value and a sign of high solvency as SNDL would need 2.69 years to pay back of all of its debts.
  • The Debt to FCF ratio of SNDL (2.69) is better than 92.71% of its industry peers.
  • A Debt/Equity ratio of 0.11 indicates that SNDL is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.11, SNDL perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 2.69
Altman-Z 1.14
ROIC/WACCN/A
WACC8.42%
SNDL Yearly LT Debt VS Equity VS FCFSNDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • SNDL has a Current Ratio of 5.04. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
  • SNDL's Current ratio of 5.04 is fine compared to the rest of the industry. SNDL outperforms 64.58% of its industry peers.
  • SNDL has a Quick Ratio of 3.54. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
  • SNDL has a Quick ratio of 3.54. This is comparable to the rest of the industry: SNDL outperforms 57.29% of its industry peers.
Industry RankSector Rank
Current Ratio 5.04
Quick Ratio 3.54
SNDL Yearly Current Assets VS Current LiabilitesSNDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 16.68% over the past year.
  • The Revenue has been growing slightly by 4.43% in the past year.
  • Measured over the past years, SNDL shows a very strong growth in Revenue. The Revenue has been growing by 70.65% on average per year.
EPS 1Y (TTM)16.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.59%
Revenue 1Y (TTM)4.43%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%5.35%

3.2 Future

  • The Earnings Per Share is expected to grow by 42.75% on average over the next years. This is a very strong growth
  • SNDL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.24% yearly.
EPS Next Y51.52%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue Next Year4.28%
Revenue Next 2Y3.84%
Revenue Next 3Y3.42%
Revenue Next 5Y3.24%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SNDL Yearly Revenue VS EstimatesSNDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
SNDL Yearly EPS VS EstimatesSNDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15

4

4. Valuation

4.1 Price/Earnings Ratio

  • SNDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • The Price/Forward Earnings ratio is 212.10, which means the current valuation is very expensive for SNDL.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SNDL indicates a somewhat cheap valuation: SNDL is cheaper than 68.23% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of SNDL to the average of the S&P500 Index (28.02), we can say SNDL is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 212.1
SNDL Price Earnings VS Forward Price EarningsSNDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 150 200

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SNDL indicates a rather cheap valuation: SNDL is cheaper than 89.58% of the companies listed in the same industry.
  • SNDL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SNDL is cheaper than 91.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.67
EV/EBITDA 10.4
SNDL Per share dataSNDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SNDL does not grow enough to justify the current Price/Earnings ratio.
  • SNDL's earnings are expected to grow with 33.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.55%
EPS Next 3Y33.21%

0

5. Dividend

5.1 Amount

  • No dividends for SNDL!.
Industry RankSector Rank
Dividend Yield 0%

SNDL INC

NASDAQ:SNDL (2/20/2026, 8:05:30 PM)

After market: 1.572 -0.01 (-0.51%)

1.58

+0.04 (+2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)03-12
Inst Owners23.09%
Inst Owner Change1.03%
Ins Owners4.34%
Ins Owner ChangeN/A
Market Cap406.69M
Revenue(TTM)951.58M
Net Income(TTM)-92.28M
Analysts82.5
Price Target5.71 (261.39%)
Short Float %0.62%
Short Ratio0.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.83%
Min EPS beat(2)-83.95%
Max EPS beat(2)119.61%
EPS beat(4)3
Avg EPS beat(4)111%
Min EPS beat(4)-83.95%
Max EPS beat(4)345.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.86%
Min Revenue beat(2)0.07%
Max Revenue beat(2)3.66%
Revenue beat(4)3
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-6.38%
Max Revenue beat(4)3.66%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-166.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 212.1
P/S 0.59
P/FCF 9.67
P/OCF 7.99
P/B 0.51
P/tB 0.61
EV/EBITDA 10.4
EPS(TTM)-0.02
EYN/A
EPS(NY)0.01
Fwd EY0.47%
FCF(TTM)0.16
FCFY10.34%
OCF(TTM)0.2
OCFY12.52%
SpS2.7
BVpS3.12
TBVpS2.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7%
ROE -8.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.03%
FCFM 6.05%
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
F-Score6
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 2.69
Debt/EBITDA 2.69
Cap/Depr 21.63%
Cap/Sales 1.28%
Interest Coverage N/A
Cash Conversion 156.16%
Profit Quality N/A
Current Ratio 5.04
Quick Ratio 3.54
Altman-Z 1.14
F-Score6
WACC8.42%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)23.85%
Cap/Sales(3y)1.2%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.59%
EPS Next Y51.52%
EPS Next 2Y43.55%
EPS Next 3Y33.21%
EPS Next 5Y42.75%
Revenue 1Y (TTM)4.43%
Revenue growth 3Y154.1%
Revenue growth 5Y70.65%
Sales Q2Q%5.35%
Revenue Next Year4.28%
Revenue Next 2Y3.84%
Revenue Next 3Y3.42%
Revenue Next 5Y3.24%
EBIT growth 1Y73.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year657.88%
EBIT Next 3Y150.28%
EBIT Next 5Y93%
FCF growth 1Y604.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4779.4%
OCF growth 3YN/A
OCF growth 5YN/A

SNDL INC / SNDL FAQ

What is the ChartMill fundamental rating of SNDL INC (SNDL) stock?

ChartMill assigns a fundamental rating of 4 / 10 to SNDL.


Can you provide the valuation status for SNDL INC?

ChartMill assigns a valuation rating of 4 / 10 to SNDL INC (SNDL). This can be considered as Fairly Valued.


What is the profitability of SNDL stock?

SNDL INC (SNDL) has a profitability rating of 2 / 10.


Can you provide the financial health for SNDL stock?

The financial health rating of SNDL INC (SNDL) is 6 / 10.